ADXNAddex Therapeutics Ltd.

Nasdaq addextherapeutics.com


$ 9.34 $ 0.39 (4.36 %)    

Friday, 10-May-2024 11:31:43 EDT
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 9.34
$ 9.33
$ 0.00 x 0
$ 0.00 x 0
$ 9.33 - $ 9.34
$ 5.00 - $ 27.90
5,587
na
1.17B
$ 1.28
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 johnson--johnson-partnered-addex-therapeutics-epilepsy-candidate-fails-mid-stage-study-stock-tanks

Latest Phase 2 epilepsy study findings on ADX71149 adjunctive therapy for focal onset seizures. Partnered with Janssen, Addex T...

 addex-therapeutics-announces-lack-of-statistical-significance-in-adx71149-phase-2-epilepsy-study

Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small m...

 earnings-scheduled-for-april-18-2024

Companies Reporting Before The Bell • Addex Therapeutics (NASDAQ:ADXN) is estimated to report earnings for its fourth quarter.

 addex-therapeutics-fy23-eps-chf-014-up-from-chf-046-yoy-income-chf-165m-up-from-chf-145m-yoy

Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024 Launched Neurosterix with Perceptive Advisors, r...

 why-skillsoft-shares-are-trading-lower-by-around-27-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter...

 why-macatawa-bank-shares-are-trading-higher-by-around-37-here-are-20-stocks-moving-premarket

Shares of Macatawa Bank Corporation (NASDAQ: MCBC) rose sharply in today’s pre-market trading after Wintrust Financial Corpora...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION